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Thyroid cancers represent about 1% of all human cancers. Differentiate thyroid carcinomas
(DTCs), papillary and follicular cancers, are the most frequent forms, instead Anaplastic
Thyroid Carcinoma (ATC) is estimated to comprise 1–2% of thyroid malignancies and it
accounts for 14–39% of thyroid cancer deaths.The annual incidence of ATC is about one to
two cases/million, with the overall incidence being higher in Europe (and area of endemic
goiter) than in USA. ATC has a more complex genotype than DTCs, with chromosomal
aberrations present in 85–100% of cases. A small number of gene mutations have been
identified, and there appears to be a progression in mutations acquired during dediffer-
entiation. The mean survival time is around 6 months from diagnosis an outcome that is
frequently not altered by treatment. ATC presents with a rapidly growing fixed and hard
neck mass, often metastatic local lymph nodes appreciable on examination and/or vocal
paralysis. Symptoms may reflect rapid growth of tumor with local invasion and/or compres-
sion.The majority of patients with ATC die from aggressive local regional disease, primarily
from upper airway respiratory failure. For this reason, aggressive local therapy is indicated
in all patients who can tolerate it. Although rarely possible, complete surgical resection
gives the best chance of long-term control and improved survival. Therapy options include
surgery, external beam radiation therapy, tracheostomy, chemotherapy, and investigational
clinical trials. Multimodal or combination therapy should be useful. In fact, surgical debulk-
ing of local tumor, combined with external beam radiation therapy and chemotherapy as
neoadjuvant (before surgery) or adjuvant (after surgery) therapy, may prevent death from
local airway obstruction and as best may slight prolong survival. Investigational clinical trials
in phase I or in phase II are actually in running and they include anti-angiogenetic drugs,
multi-kinase inhibitor drugs.
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EPIDEMIOLOGY
The majority of thyroid malignancies are well-differentiated and
have an excellent prognosis, on the other hand Anaplastic Thyroid
Carcinoma (ATC) is an extremely aggressive cancer representing
one of the most aggressive in humans with a dismal prognosis
despite various therapeutic modalities. Although ATC accounts
only for 2% of thyroid cancer incidence, it accounts for 14–39%
of thyroid cancer deaths (Hundahl et al., 1998; Kitamura et al.,
1999).
The female/male ratio is 5 to 1 and the peak of incidence is in
the sixth and seventh decades of life (Kebebew et al., 2005). These
observations are confirmed by other studies have demonstrated
that about 68% of ATC patients were over 70 years of age and
females constituted 70% and males 30% (Hundahl et al., 2000).
The incidence of ATC is estimated at one to two cases per mil-
lion population per year, and the trend has been decreasing even
though the incidence of well-differentiated subtypes (e.g., papil-
lary and follicular) of thyroid cancer has been increasing (Davies
and Welch, 2006).
RISK FACTOR
Risk factors for ATC are not well understood, in fact ATC might
occur in patient without history of thyroid disease, or on the other
hand, could have a history of goiter, or on histological examina-
tion, could co-exist differentiated thyroid cancer. In a study was
demonstrated that 25% of the ATC patients had a prior history of
thyroid goiter and another 10% with family history of goiter and
it is also known that ATC is more common in places with endemic
goiter as demonstrated by decreased incidence of ATC after iodine
salt supplementation (Besic et al., 2010).
GENETIC ALTERATIONS
Recent advances in understanding the genetic and molecular
pathogenesis of ATC hold promise for target therapy. ATC shows
only few specific gene mutations, and the majority occurs in PTC
(e.g., RAS and BRAF; Smallridge et al., 2009). This implies that
many ATCs derive from preexisting PTCs by a process of dedif-
ferentiation, acquiring new mutations like p53, catenin (cadherin-
associated protein), beta 1, and PIK3CA (Nuocera et al., 2011).
The remaining part of ATC may derive “de novo,” in this even-
tuality ATC is found alone in the removed thyroid (Nikiforov,
2004).
Genetic alterations in p53 gene are the most frequent in ATCs
(55%), the other mutations follow for frequency as reported: RAS
(22%), BRAF (26%), b-catenin (38%), PIK3CA (17%; Smallridge
and Copland, 2010).
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p53 GENE
It is a tumor suppressor gene located on chromosome 17p. P53
plays a key role in its nuclear transcription of factor production
and in regulation of the cell cycle, DNA repair, and apoptosis.
Mutations of p53 gene result in growth, angiogenesis, and ded-
ifferentiation (O’Neill et al., 2010). Antico Arciuch et al. (2011)
recently presented a paper with the characterization of the first
mouse model of ATC, derived from the inactivation of p53 in
cavies with constitutional activation of PI3CA.
BRAF
It is the most common mutation in papillary thyroid cancer and it
is involved in tumor progression like radioactive iodine refractori-
ness and PTC recurrence (Nucera et al., 2010). BRAF mutations
can be observed in both differentiated and undifferentiated tissues
when ATCs co-exist with PTCs (Begum et al., 2004; Soares et al.,
2004).
RAS
It is a family of oncogenes important as cell growth regula-
tors and they have a role in thyroid differentiation (Santarpia
et al., 2008). The most important signal transduction pathway,
for tumorigenesis, is the Ras-MAPK and phosphatidylinositol
3-kinase (PI3K)/Akt pathways (Luo et al., 2003).
b-CATENIN ANDWnt PATHWAYS GENES
b-Catenin is a multifunctional protein and has two distinct func-
tions. At first it binds as an intracellular stabilizer to cadherins
to form the adherence junction. Dissociation of b-catenin from
E-cadherin, mediated by various TKs, favors cell migration, and
formation of metastases. At second, activation of Wnt signaling
pathway stabilizes cytosolic b-catenin. This mechanism could be
lost in presence on b-catenin mutations (Rao et al., 2006).
PIK3CA
Among PI3Ks there are several classes, but the most important in
human tumorigenesis and it is also the well characterized. It consist
of heterodimers of a regulatory subunit and one of p110 catalytic
subunits. The A and B types (respectively PIK3CA e PIK3CB) play
an important role in human cancers (Xing, 2010). PIK3CA gene is
located on 3q26.3 and its mutations are extremely rare in follicular
or papillary thyroid carcinomas (Liu et al., 2008).
CLINICAL PRESENTATION
Clinically, ATC can present as a rapidly progressing disease invad-
ing surrounding local tissues and metastasizes to distant organs.
Locally, ATC shows a rapidly enlarging anterior neck mass,
with accompanying dysphagia (40%), voice change or hoarse-
ness (40%), and stridor (24%). Regional symptoms included a
noticeable lymph node mass (54%) and neck pain (26%). Sys-
temic symptoms include anorexia, weight loss, and shortness of
breath with pulmonary metastases. ATC is usually advanced at
diagnosis and frequently surgically unresectable (Kebebew et al.,
2005; Besic et al., 2010). Around 20–50% of patients present with
distant metastases, most often pulmonary (Nuocera et al., 2011),
and another 25% develop new metastasis during the rapid course
of the disease [Lungs (80%), bone (6–16%), and brain (5–13%)
were the most common sites of metastasis; Tennvall et al., 2002].
PROGNOSIS
The three different morphologic patterns identifiable at histologic
analysis (squamoid, spindle cell, and giant cell) present similar
biological and clinical features and none influences the prognosis
(Hundahl et al., 1998).
Some factors as age, gender, tumor size, extent of disease, and
resectability, influence clinical course and prognosis, however the
median survival is usually less than 6 months, and death is either
due to uncontrolled local invasion or distant metastasis. Younger
female patients (<65 years old), with a small ATC (less than 5 cm
or intra-thyroidal) and no distant metastasis at diagnosis, have
a better prognosis (Rosai et al., 1993). Local disease consists in
tracheal and esophageal invasion and obstruction (Pasieka, 2003;
Kihara et al., 2004).
In an analysis of survival of ATC patients from the SEER data-
base from 1983 to 2002, which included patients who survived
for more than a month, the median survival was 4 months. On
multivariate analysis, distant, or metastatic disease, tumor size
greater than 7 cm, and treatment with surgery with or without
radiotherapy were statistically significant prognostic markers with
poor outcomes (P ≤ 0.05). Of interest, patients with extracapsular
extension into adjacent tissue, the addition of radiotherapy was
of benefit, on the contrary radiotherapy after surgery was of no
benefit in patients who had disease confined to the thyroid or
had distant metastasis (Sniezek, 2003). Age, sex, size of the tumor,
resectability, and the extent of disease has been shown to affect
the course of the disease (Chen et al., 2008). In a SEER-based
study in the United States by multivariate analysis, only age less
than 60 years, an intra-thyroidal tumor, and the combined use of
surgical and external beam radiation therapy were identified as
independent predictors of lower cause-specific mortality (McIver
et al., 2001). In other series, female sex, tumor size less than 6 cm,
age, and the extent of disease were the most favorable prognostic
markers (Tan et al., 1995; Dziba et al., 2002). Among Koreans less
than 60 years of age, tumor size less than 7 cm, and lesser disease
burden were independent predictors of lower mortality (Lo et al.,
1999). A recent study from France based on 26 patients with ATC,
univariate analysis showed that age above 75, capsular invasion,
lymph nodes metastasis, residual tumor after surgery, and lack
of multimodal treatment (particularly radiotherapy in patients
without tumor residue) are poor prognostic factors. Multivariate
analysis in the same cohort showed age above 75, followed by node
invasion, capsular invasion, and female sex to be poor prognosti-
cators (Roche et al., 2010). In a study by Venkatesh and colleagues,
patients with localized disease had a median survival of 8 months
in comparison to 3 months for patients with metastatic disease
(Tan et al., 1995; Lo et al., 1999; Kim et al., 2007; Roche et al.,
2010). A prognostic index was developed by Sugitani et al. (2001)
from a review of their series of 47 patients over 33 years (Venkatesh
et al., 1990). Their index was based on a combination of four risk
factors: (Hundahl et al., 1998; Kitamura et al., 1999) presence of
acute symptoms, (Kebebew et al., 2005) tumor size greater than
5 cm, (Hundahl et al., 2000) distant metastasis, and (Davies and
Welch, 2006) white cell count≥10,000/µL (Venkatesh et al., 1990).
Patients with a prognostic index less than or equal to one had a
62% survival rate at 6 months, whereas all patients with prognostic
index of three and four died within 6 and 3 months, respectively.
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TREATMENT
Patients with ATC even in the absence of metastatic disease are
considered to have systemic disease at the time of diagnosis. All
ATCs are considered stage IV by the International Union Against
Cancer (UICC) – TNM staging and American Joint Commission
on Cancer (AJCC) system. Multimodality treatment consisting of
surgery when feasible combined with radiation and chemotherapy
is generally recommended.
SURGERY
The aim of surgery is to obtain a complete macroscopic resection,
with microscopically clear resection margins. Complete resec-
tion has been identified as a prognostic factor in several clini-
cal trials (Junor et al., 1992; Tan et al., 1995; Kobayashi et al.,
1996; Sugitani et al., 2001). When feasible, surgery must aim at
a radical intent. The categories of patients that may be most
suitable for this approach are young patients (<65 years old)
with small lesions (<6 cm) and no distant metastasis. However,
surgery also plays an important role for palliation. Partial resec-
tion of the tumor followed by radiotherapy and chemotherapy
may delay or avoid airway obstruction, although it can improve
survival only by a few months (Nel et al., 1985). It is theo-
retically possible that, in selected patients, even in the setting
of metastatic disease, surgery may result in an improved qual-
ity of life and prevent death from suffocation (Miccoli et al.,
2007).
Since surgery alone is not able to control the disease even in
patients with small intra-thyroidal masses, adjuvant therapy is
always required, and can be administered either with radiother-
apy (RT) or chemoradiotherapy. Whether surgery should be given
up-front or after neoadjuvant treatment is a matter of debate. In
fact, primary chemotherapy might make inoperable lesions oper-
able, with the additional potential advantage of preventing distant
metastasis. Moreover, Tennvall et al. (2002) reported encouraging
results analyzing the outcome of 55 patients with ATC treated
with neoadjuvant chemoradiotherapy between 1984 and 1999.
The response to primary treatment was 72% (Yau et al., 2008).
SYSTEMIC TREATMENT
Cytotoxic agents
Anaplastic thyroid carcinoma cannot be regarded as a very chemo-
sensitive tumor. Doxorubicin is not able to achieve more than a
20% response rate (Pacini et al., 1984). In a randomized study
(Shimaoka et al., 1985) observed that combination chemother-
apy based on doxorubicin (60 mg/m2) and cisplatin (40 mg/m2)
was more effective than doxorubicin alone and provided a higher
complete response rate. More recently, single drug docetaxel
was tested as first-line chemotherapy in patients with advanced
ATC. In a prospective phase II clinical trial of paclitaxel, 20
patients with metastatic ATC were enrolled and a remarkable
response rate of 53% was obtained (Schoenberger et al., 2004).
In a preclinical experiment (Schoenberger et al., 2004) only
paclitaxel, gemcitabine, and vinorelbine appeared to be active
in ATC (Bauer et al., 2003) and the combinations of vinorel-
bine/gemcitabine and paclitaxel/gemcitabine seemed to act syn-
ergistically. These results should receive confirmation in clinical
trials.
Anti-angiogenetic agents
A common feature of thyroid cancers is their markedly increased
vascularization, with an elevated expression of the vascular
endothelial growth factor (VEGF) by immunohistochemistry,
compared with normal thyroid tissue (Klein et al., 1999; Bauer
et al., 2003). VEGF levels are correlated with stage, tumor size,
nodal involvement, extra-thyroidal invasion, and distant metas-
tases (Chaplin et al., 1996). On the basis of these findings, several
drugs targeting angiogenesis have been evaluated against ATC.
• Combretastatin A4 phosphate (CA4P): is a tubulin-binding
vascular disrupting agent that inhibits tumor blood flow. In
contrast to other anti-angiogenetic drugs that block the forma-
tion of new vessels in tumors,vascular disrupting agents (such as
CA4P) stop blood flow through already existing vessels, with the
result of depriving tumor cells of oxygen and nutrients (McIver
et al., 2001; Tozer et al., 2002). CA4P has activity against ATC cell
lines and xenograft (Dowlati et al., 2002). In a phase I trial (Inai
et al., 2004), one patient with ATC showed a progression-free
survival of 30 months, however, the drug was found to be associ-
ated with significant cardiovascular side effects at the escalating
doses employed.
• Axitinib (AG-013736) is an oral, potent, and selective inhibitor
of VEGFRs 1, 2, and 3. Preclinical studies demonstrated that
axitinib rapidly and selectively inhibits VEGF-dependent fen-
estrations and VEGFR-2 and 3 expression in endothelial cells,
with the result of blocking angiogenesis and tumor blood flow
(Baffert et al., 2006; Kamba et al., 2006; Mancuso et al., 2006;
Mooney et al., 2009). The principal mechanism of action of
axitinib is inhibition of VEGF signaling (Bauer et al., 2002).
• Bevacizumab (a monoclonal antibody anti VEGF) was tested
alone and in combination with cetuximab in an in vivo model
compared with doxorubicin. This study demonstrated that both
drugs, either alone or in combination, inhibited tumor growth
and angiogenesis better than doxorubicin (Prichard et al., 2007).
• AZD2171, a tyrosine-kinase inhibitor of the VEGFR-1 and
VEGFR-2, blocked tumor growth and prolonged survival of
ATC-bearing mice (Gomez-Rivera et al., 2007).
Histone deacetylase inhibitors
Histone deacetylase inhibitors are a promising class of antineo-
plastic agents that are able to induce cell differentiation, cell cycle
arrest, and apoptosis through hyperacetylation of histones, with
the potential to enhance the cytotoxicity of drugs such as doxoru-
bicin. Preclinical studies have shown that valproic acid, a potent
anti-convulsant agent, is able to enhance the activity of doxoru-
bicin in cell lines derived from ATC alone or in combination with
other drugs (Catalano et al., 2006; Kim et al., 2009).
Tyrosine-kinase inhibitors
• Imatinib (STI571) is an oral inhibitor of the ABL kinase (the
product of the fusion of Bcr and Abl gene). In addition, it
can specifically inhibit c-Kit and PDGF receptors, which are
hyper-functioning in some malignancies. On the basis of the
assumption that ATC which overexpresses PDGFR and/or Abl
might respond to imatinib.
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• Sorafenib (Bay43-9006, Nexavar) is an oral, small tyrosine-
kinase inhibitor of the Raf protein kinase receptor, VEGFR-2,
and PDGF-β and displays strong anti-angiogenetic activity.
Sorafenib demonstrates an acceptable response rate in pre-
treated ATC patients and further clinical studies are warranted.
Anti-EGFR agents
The epidermal growth factor receptor (EGFR) has been implicated
in the pathogenesis of several types of cancer. There is supporting
evidence that EGFR is expressed at high levels in ATC and papillary
thyroid cancers (van der Laan et al., 1995). EGFR was expressed
in all of the ATC cell lines examined and non-ligand dependent
phosphorylation of EGFR was identified in half of the cell lines
(Bergström et al., 2000). High expression of EGFR appears to be a
negative prognostic factor in many types of tumors, but few studies
have examined its prognostic role in thyroid cancers (Mizukami
et al., 1991). Strong EGFR staining in papillary thyroid cancer was
associated with poor prognosis (Akslen et al., 1993). These find-
ings suggest that inhibition of EGFR may have anti-cancer efficacy
in ATC.
• Gefitinib (ZD1839) is an orally active EGFR inhibitor that
blocks EGFR-mediated downstream signal transduction. Pre-
clinical trials have tested the activity of this drug against in vitro
or in vivo models of ATC. Moreover Pennell et al studied the
efficacy of gefitinib in a large group of thyroid cancer, includ-
ing anaplastic thyroid cancer. Although gefitinib therapy did
not result in any complete responses, the 32% of all patients
underwent therapy with gefitinib have had reductions in tumor
volume and prolonged stable disease, for the authors this may
indicate biologic activity (Pennel et al., 2008).
• Cetuximab (C225) is a human-murine chimeric monoclonal
antibody against EGFR. It has been approved by the Food
and Drug Administration (FDA) for use in metastatic colorec-
tal cancer and head and neck squamous cell carcinoma either
metastatic or unresectable.
Agents targeting the NF-κB pathway
The 26s proteasome is a large ATP-dependent multimeric com-
plex that degrades intracellular proteins that have been marked
for proteolysis by the process of ubiquitination (Adams, 2004).
The ubiquitin-proteasome pathway plays a significant role in neo-
plastic growth and metastatic spread. The proteasome is also
required for activating nuclear factor κB (NF-κB) by degrada-
tion of its inhibitory protein factor κB inhibitor (I-κB). NF-κB
is a transcription factor that upregulates a number of proteins
involved in cancer progression including several anti-angiogenetic
and anti-apoptotic factors (Aghajanian et al., 2005).
• Bortezomib (PS-341) is a proteasome inhibitor that has been
approved by the FDA for the treatment of multiple myeloma
and its mechanisms of action include the inhibition of I-κB,
which leads to inactivation of the transcriptional factor NF-
κB (Davis et al., 2004; Papandreou et al., 2004). NF-κB is
often constitutively activated in medullary thyroid carcinoma
and ATC, and is therefore implicated in their pathophysiol-
ogy (Pacifico et al., 2004). Bortezomib has also been shown
to increase the expression of TRAIL (TNF-related-apoptosis-
induced-ligand) receptors (TRAIL-R1 and 2) and to sensitize
tumors to TRAIL-mediated killing (Conticello et al., 2007). The
high cytotoxic activity and good in vivo tolerability of borte-
zomib holds promise for its future use in the treatment of ATC
patients.
Agents targeting farnesyl-transferase
A new group of therapeutic agents called farnesyl-transferase
inhibitors (FTIs) has been used in the treatment of solid
tumors. Activating Ras mutations are common in thyroid can-
cers (Wynford-Thomas, 1997). Ras, the protein product of the Ras
proto-oncogene, requires post-translational modification by con-
jugation of a farnesyl moiety to its C-terminal amino-acid. After
farnesylation, Ras is localized to the inner surface of the cell mem-
brane and is able to transduce the mitogenic signals mediated by
tyrosine-kinase receptors. Farnesylation-blocking agents therefore
operate by inhibiting Ras activity.
• Manumycin A is a natural product of Streptomyces parvulus that
inhibits farnesyl-transferase and has antitumor activity against
a variety of cancers in vitro and in xenograft models (Ito et al.,
1996; Nagase et al., 1996). Apart from inhibition of angiogenesis,
manumycin A causes apoptosis by inducing the pro-apoptotic
protein Bax (Pan et al., 2005). No clinical trials have been per-
formed to determine the activity and/or efficacy of manumycin
A against ATC.
Proteasome inhibitor
PI3 kinase and MAPK pathways bind to heat shock protein 90
(HSP90). Disruption of HSP90 lead to reduced cell signaling
and to cell death. Many cancer’s cells demonstrated an over-
activation of HSP90, so HSP90 inhibitors have been developed
(Braga-Basaria et al., 2004).
• Geldanamycin is a benzoquinoid ansamycin antibiotic that
works via the dissociation of the HSP90, affecting the stability
and the steady state level of these oncoproteins. Park et al. (2003)
demonstrated in vitro that geldanamycin inhibits thyroid can-
cer cell proliferation, down-regulates oncoproteins, and inhibits
EGF-induced invasion. However Geldanamycin is weighed by
important hepatic toxicity (Neckers, 2002).
• 17-Allylamino-17-demethoxygeldanamycin (17-AAG) 17-AAG
maintains similar antitumor properties of geldanamycin but has
fewer associated side effects. 17-AAG binds the ATP-binding
pocket in the amino terminus of Hsp90, thereby inhibiting
Hsp90 function (Neckers, 2002). Braga-Basaria and colleagues
evaluated in vitro the activity of 17-AAG on cancer cells. Of the
various cancer’s cells lines, the most enhanced pro-apoptotic
effects was demonstrated for those cell lines with highest level
of HSP 90; thus, although not clearly applied yet to anaplas-
tic thyroid cancer cells, the data suggest that HSP90 levels may
serve as a biomarker for 17-AAG activity (Braga-Basaria et al.,
2004).
Agents targeting matrix metalloproteinases
Matrix metalloproteinases (MMPs) are an important group of
enzymes mediating the endothelial cell invasion and migration
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required for the formation of new capillaries, a crucial step in the
angiogenesis process.
• Minocycline is a semi-synthetic analog of tetracycline active
against MMPs through chelation of the zinc ion at the active site
of the enzyme. In a preclinical study, She and Jim (2006) inves-
tigated the effect of adding minocycline to manumycin A and
paclitaxel against human ATC cells xenografted in nude mice,
and demonstrated that the triple-drug combination resulted
in the lowest average tumor growth rate, yielding significantly
better survival than manumycin A alone, paclitaxel alone, or
manumycin A plus paclitaxel. This novel combination deserves
further investigation for the treatment of ATC.
Agents targeting PPARγ
Peroxisome proliferator-activated receptor gamma (PPARγ) ago-
nists have demonstrated antitumor activity against a vari-
ety of human cancers in preclinical models and clinical trial
(Zang et al., 2003). The mechanism of action of the differ-
ent classes of these compounds, which comprise non-steroidal
anti-inflammatory drugs, amino-acid derivatives, polyunsatu-
rated fatty acids, eicosanoids, and thiazolidinediones, is attributed
to the capacity of binding and activating PPARγ. PPARγ acts as
a tumor suppressor gene, upregulating important enzymes which
control the cell cycle (Nakajima et al., 2001).
Thiazolidinediones represent the most widely investigated
pharmaceutical class among PPARγ agonists (Aiello et al., 2006).
In a preclinical study, two agents belonging to this class, ciglitazone
and rosiglitazone, showed promising biological effects in ATC cells,
such as an increased rate of apoptosis and inhibition of anchorage-
dependent and -independent growth and migration. Furthermore,
rosiglitazone increased the expression of thyroid-specific differen-
tiation markers, thus inducing a partial reversion of the epithelial-
mesenchymal transition in ATC cells, which correlates with ATC
growth and dissemination (Weng et al., 2006).
RS5444 is another thiazolidinedione agent and a PPARγ ago-
nist. RS5444 demonstrated antitumor activity in preclinical stud-
ies, with a mechanism which includes the transactivation of genes
regulating cell proliferation, apoptosis, and differentiation. In par-
ticular, PPARγ activation is able to upregulate p21 protein, which
is known to complex and inhibit an heterodimeric complex called
cyclin dependent kinase 2 (CDK2)-cyclin E/A, responsible for cell
cycle progression. Cells expressing nuclear p21 are subsequently
arrested in the G0–G1 phase of the cell cycle (Pei and Xiong,
2005).
RADIATION
Radiation does not alter the course of ATC in most patients. On
the other hand, when combined with surgery and chemother-
apy, it can prolong the short-term survival in select and sub-
set of patients. Intensity-modulated radiation therapy (IMRT)
based on computerized treatment planning and delivery is able
to generate a dose distribution that delivers radiation accu-
rately with sparing of the surrounding normal tissue (Rosen-
bluth et al., 2005; Lee et al., 2007). Higher doses of radiation
can be given over a shorter time with less toxicity by employ-
ing hyperfractionation techniques (Tennvall et al., 1990; Wong
et al., 1991). Toxicity can be a limiting factor with radiation. Kim
and Leeper (1987) reported complications particularly, pharyngi-
tis, esophagitis, and tracheitis in their series. Wong et al. (1991) also
noted skin changes, esophageal toxicity, and radiation myelopa-
thy. Daily doses of greater than 3Gy should be cautiously used
as it can increase the incidence of myelopathy (Wong et al.,
1991).
More encouraging are the results reported by the concurrent
use of taxanes and radiation. After standard dose of 60Gy in 30
fractions along with docetaxel 100 mg every 3 weeks for six cycles,
an improvement of disease with partial remission (33%) and com-
plete response (64%) was observed in ATC patients (Troch et al.,
2010; Brierley, 2011).
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